



**HAL**  
open science

## **P18-01. Exquisite specificity of CTL response to the M184V mutation**

Yves Pacheco, Clotilde Allavena, Yannick Guilloux, Virginie Ferré, François Raffi, Dorian Mcilroy

► **To cite this version:**

Yves Pacheco, Clotilde Allavena, Yannick Guilloux, Virginie Ferré, François Raffi, et al.. P18-01. Exquisite specificity of CTL response to the M184V mutation. AIDS Vaccine 2009, Oct 2009, Paris, France. pp.P310, 10.1186/1742-4690-6-S3-P310 . inserm-00663920

**HAL Id: inserm-00663920**

**<https://inserm.hal.science/inserm-00663920>**

Submitted on 27 Jan 2012

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Poster presentation

## **P18-01. Exquisite specificity of CTL response to the M184V mutation**

Y Pacheco<sup>3</sup>, C Allavena<sup>1</sup>, Y Guilloux<sup>2</sup>, V Ferre<sup>3</sup>, F Raffi<sup>1</sup> and D McIlroy<sup>\*3</sup>

Address: <sup>1</sup>Dept. Maladies Infectieuses, Hotel-Dieu Hospital, Nantes, France, <sup>2</sup>INSERM U 892, University of Nantes, Nantes, France and <sup>3</sup>EA 4271 University of Nantes, Dept. Virology, Hotel-Dieu Hospital, Nantes, France

\* Corresponding author

from AIDS Vaccine 2009  
Paris, France. 19–22 October 2009

Published: 22 October 2009

*Retrovirology* 2009, **6**(Suppl 3):P310 doi:10.1186/1742-4690-6-S3-P310

This abstract is available from: <http://www.retrovirology.com/content/6/S3/P310>

© 2009 Pacheco et al; licensee BioMed Central Ltd.

### **Background**

The M184V mutation confers resistance to lamivudine and emtricitabine and falls within a HLA-A2 restricted CTL epitope, RT181-189, suggesting that it could be possible to vaccinate against drug resistance. In ART naïve patients, CTL directed against this epitope recognize both the wild-type 184M peptide, and the 3TC-resistant 184V peptide, while in patients with 3TC-resistant virus it is possible to detect CTL against the 184V peptide that do not cross-react with the 184M peptide. To determine whether the 184V or the 184M peptide would be the best candidate for therapeutic vaccination, we studied the specificity and functional avidity of clones and cell lines specific for the RT181-189 epitope.

### **Methods**

CTL lines and clones were obtained from PBMC of one ART naïve HLA-A2+ patient and two HLA-A2+ patients with lamivudine-resistant virus. Functional responses to a panel of variant peptides were studied using IFN-gamma ELISPOT.

### **Results**

One 184M/184V cross-reactive clone and two CTL lines specific for 184V were obtained. The cross-reactive clone showed high functional avidity (EC<sub>50</sub> 100 pM) for both 184M and 184V peptides, and also recognized 184I, 184A, 184G, 184F and 184D mutant peptides. Both cell lines from patients with 3TC-resistant virus showed selectivity for 184V. Although the functional avidities of the two cell lines were lower (EC<sub>50</sub> 1 nM and 1 μM) than that

found in the cross-reactive clone, they fell within the range of values observed in PBMC from HLA-A2+ ART-naïve patients showing a cross-reactive ELISPOT response to the 184M and 184V peptides.

### **Conclusion**

The CTL response directed specifically against the 184V peptide is characterized by high selectivity, and its functional avidity is similar to that of the cross-reactive response generated against the 184M peptide.